MedTrace Logo

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

NCT02601378 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2022-09-29

No results posted yet for this study

Summary

This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.

Conditions

Interventions

DRUG

LXS196

LXS196 as a single agent

DRUG

LXS196 and HDM201

LXS196 in combination with HDM201

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-01
Primary Completion
2022-01-07
Completion
2022-01-07
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Netherlands
  • Norway
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02601378 on ClinicalTrials.gov